- Home
- ESNT vs RLAY Comparison
ESNT vs RLAY Comparison
Compare ESNT & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESNT
- RLAY
- Stock Information
- Founded
- ESNT 2008
- RLAY 2015
- Country
- ESNT Bermuda
- RLAY United States
- Employees
- ESNT N/A
- RLAY N/A
- Industry
- ESNT Property-Casualty Insurers
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESNT Finance
- RLAY Health Care
- Exchange
- ESNT Nasdaq
- RLAY Nasdaq
- Market Cap
- ESNT N/A
- RLAY 803.4M
- IPO Year
- ESNT 2013
- RLAY 2020
- Fundamental
- Price
- ESNT $60.13
- RLAY $7.05
- Analyst Decision
- ESNT Buy
- RLAY Strong Buy
- Analyst Count
- ESNT 6
- RLAY 8
- Target Price
- ESNT $65.67
- RLAY $17.25
- AVG Volume (30 Days)
- ESNT 654.2K
- RLAY 1.7M
- Earning Date
- ESNT 11-07-2025
- RLAY 11-05-2025
- Dividend Yield
- ESNT 2.06%
- RLAY N/A
- EPS Growth
- ESNT N/A
- RLAY N/A
- EPS
- ESNT 6.85
- RLAY N/A
- Revenue
- ESNT $1,268,306,000.00
- RLAY $8,355,000.00
- Revenue This Year
- ESNT $4.27
- RLAY $27.33
- Revenue Next Year
- ESNT $1.47
- RLAY $7.40
- P/E Ratio
- ESNT $8.77
- RLAY N/A
- Revenue Growth
- ESNT 5.28
- RLAY N/A
- 52 Week Low
- ESNT $51.61
- RLAY $1.78
- 52 Week High
- ESNT $65.90
- RLAY $7.19
- Technical
- Relative Strength Index (RSI)
- ESNT 43.94
- RLAY 73.41
- Support Level
- ESNT $58.46
- RLAY $6.31
- Resistance Level
- ESNT $61.02
- RLAY $7.18
- Average True Range (ATR)
- ESNT 1.01
- RLAY 0.43
- MACD
- ESNT -0.22
- RLAY 0.06
- Stochastic Oscillator
- ESNT 25.43
- RLAY 93.55
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).